What is the difference between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Focal ductal carcinoma in situ (DCIS) should be treated with lumpectomy or total mastectomy, often followed by radiation therapy, to reduce recurrence rates and prevent potential progression to invasive ductal carcinoma (IDC) 1. When comparing focal ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC), it is essential to consider their distinct behaviors and treatment approaches. Focal DCIS is a non-invasive breast cancer where abnormal cells remain confined within the milk ducts without spreading to surrounding breast tissue. In contrast, invasive ductal carcinoma has broken through the duct walls and invaded surrounding breast tissue, with potential to spread to lymph nodes and other parts of the body.

Key differences in treatment

  • DCIS treatment typically involves surgery (lumpectomy or mastectomy) often followed by radiation therapy, as outlined in the guidelines for breast cancer management 1.
  • IDC requires more aggressive treatment, including surgery, radiation, and frequently chemotherapy, hormone therapy, or targeted therapy, depending on the cancer's characteristics.

Prognosis and risk profile

  • The prognosis for DCIS is generally excellent, with nearly 100% survival rates when properly treated 1.
  • IDC prognosis varies based on stage, grade, and molecular subtype.

Importance of distinction

  • The distinction between DCIS and IDC is critical for determining appropriate treatment and understanding the patient's risk profile.
  • DCIS is sometimes considered a precursor to invasive cancer if left untreated, while IDC represents a more advanced disease state requiring more comprehensive intervention 1. Some key factors to consider in the management of DCIS include:
  • Tumor size and grade
  • Margin status
  • Patient age
  • Estrogen receptor (ER) status
  • Genetic counseling for high-risk patients 1.

From the Research

Focal Ductal vs Invasive Ductal Carcinoma

  • Focal ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) are two different types of breast cancer, with DCIS being a non-invasive form and IDC being an invasive form 2, 3.
  • The treatment and management of DCIS and IDC differ, with DCIS often being treated with lumpectomy and radiation, while IDC may require more aggressive treatment such as mastectomy and chemotherapy 3, 4.
  • The prognosis and outcomes for DCIS and IDC also differ, with DCIS having a lower risk of recurrence and mortality compared to IDC 3, 5.
  • In some cases, patients may have both DCIS and IDC, or may have synchronous bilateral breast cancers with different histological subtypes, which can pose a significant clinical challenge and require an individualized approach to management 5, 6.

Treatment Options

  • For DCIS, treatment options may include lumpectomy and radiation, or mastectomy, depending on the size and location of the tumor, as well as the patient's preferences and overall health 2, 3.
  • For IDC, treatment options may include mastectomy, chemotherapy, and radiation, depending on the stage and aggressiveness of the tumor, as well as the patient's overall health and preferences 3, 5.
  • In some cases, patients with IDC may also receive targeted therapies such as endocrine therapy or HER2-targeted therapy, depending on the tumor's hormone receptor and HER2 status 5, 6.

Prognosis and Outcomes

  • The prognosis and outcomes for DCIS and IDC differ, with DCIS having a lower risk of recurrence and mortality compared to IDC 3, 5.
  • For patients with DCIS, the risk of recurrence is generally low, but can be influenced by factors such as the size and location of the tumor, as well as the patient's overall health and treatment options 2, 3.
  • For patients with IDC, the risk of recurrence and mortality is generally higher, but can be influenced by factors such as the stage and aggressiveness of the tumor, as well as the patient's overall health and treatment options 3, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.